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Abstract    
Annexin A1 (AnxA1) is a glucocorticoid-
regulated protein known for its anti-
inflammatory and proresolving effects. We have 
previously shown that cAMP enhancing 
compounds rolipram (ROL - a PDE4 inhibitor) 
and db-cAMP (cAMP mimetic) drive caspase-
dependent resolution of neutrophilic 
inflammation. In this follow up study, we 
investigated whether AnxA1 could be involved 
in the proresolving properties of these 
compounds using a model of LPS-induced 
inflammation in BALB/c mice. The treatment 
with ROL or db-cAMP at the peak of 
inflammation shortened resolution intervals, 
improved resolution indices and increased 
AnxA1 expression. In vitro studies showed that 
ROL and db-cAMP induced AnxA1 expression 
and phosphorylation and this effect was 
prevented by PKA inhibitors, suggesting the 
involvement of PKA on ROL-induced AnxA1 
expression. Akin to these in vitro findings, H89 
prevented ROL and db-cAMP-induced 
resolution of inflammation, and it was associated 
with decreased levels of intact AnxA1. 
Moreover, two different strategies to block the 
AnxA1 pathway - by using BOC-1 a 
nonselective AnxA1 receptor antagonist or by 
using an anti-AnxA1 neutralizing antiserum - 
prevented ROL and db-cAMP-induced 
resolution and neutrophil apoptosis. Likewise, 
the ability of ROL or db-cAMP to induce 
neutrophil apoptosis was impaired in AnxA 
knockout mice. Finally, in in vitro settings ROL 
and db-cAMP overrode the survival-inducing 
effect of LPS in human neutrophils in an 
AnxA1dependent manner. Our results show that 
AnxA1 is at least one of the endogenous 
determinants mediating the proresolving 




Annexin A1 (AnxA1, previously known 
as lipocortin-1) is a 37-kDa member of the 
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Annexin superfamily which is composed by 
proteins that bind to cellular membranes in a 
calcium-dependent manner. Originally described 
as an endogenous mediator of the anti-
inflammatory effects of glucocorticoids, over the 
past 20 years AnxA1 has been shown to have a 
broad range of molecular and cellular actions, 
including modulation of leukocyte migration in 
acute and chronic inflammation, kinase activities 
in signal transduction, preservation of 
cytoskeleton and extracellular matrix integrity, 
tissue maintenance and apoptosis, cell growth 
and differentiation (1-5). AnxA1 is particularly 
abundant in cells of the myeloid lineage, 
including neutrophils, eosinophils, macrophages 
and mast cells (6). In resting cells, AnxA1 is by 
and large localized in the cytosol and, upon 
activation it can be secreted and then 
resynthesized. Once in the extracellular medium, 
this protein exerts autocrine, paracrine and 
juxtacrine effects which are mediated by the 
FPR2/ALX receptor (7-11). 
AnxA1 exerts a variety of anti-
inflammatory effects, including inhibition of 
leukocyte migration, direct inhibition of 
cytosolic phospholipase A2 (cPLA2), inhibition 
of COX-2 and iNOS expression and stimulation 
of IL-10 release (12-18). AnxA1 also possesses 
genuine proresolving properties by inducing 
neutrophil apoptosis (10,19,20) and increasing 
the clearance of apoptotic cells by efferocytosis 
(10,21-23). Both apoptosis and efferocytosis 
modulated by AnxA1 are crucial for resolution 
of inflammation (10,20). 
In the context of the discovery of new 
mechanisms for known drugs, production and 
action of AnxA1 has been shown to be involved 
in the proresolution effects of histone 
deacetylase (HDAC) inhibitors (24), as well as 
in the anti-inflammatory effects of propofol (25) 
and cromoglycate-like compounds (6,26). We 
have previously shown that rolipram (ROL), a 
selective phosphodiesterase-4 (PDE4) inhibitor 
that increases intracellular levels of cyclic 
adenosine monophosphate (cAMP), induces 
resolution of neutrophilic inflammation and it 
was associated to increased accumulation of 
AnxA1 in inflammatory cells (20). However, the 
relevance and mechanisms underlying ROL-
induced AnxA1 expression remain unknown. 
In addition to the known anti-
inflammatory properties of cAMP-elevating 
agents (27-29), emerging data support a role for 
cAMP in some steps of the resolution process 
(30-37). Indeed, cAMP elevation promoted by 
treatment with ROL or by cAMP mimetic drugs 
during established eosinophilic or neutrophilic 
inflammation induced resolution of 
inflammation via protein kinase A (PKA), the 
best known cAMP effector (3,32). Of note, 
modulation of cAMP may account for the 
proresolving abilities of melanocortins peptides 
(38) and lysophosphatidylserine (39). In this 
study, we investigated the ability of ROL and 
db-cAMP to modulate AnxA1 expression and 
wondered whether AnxA1 was involved in the 
proresolving ability of these compounds. Our 
results demonstrate that AnxA1 is induced by 
cAMP elevating agents and is indeed involved in 
the proresolving properties of these compounds, 
pointing them as potential therapeutic tools to 
control inflammatory diseases and induce 




Rolipram and db-cAMP promote 
resolution of neutrophilic inflammation 
associated with increased AnxA1 expression. 
Initially, we evaluated whether ROL (PDE4 
inhibitor) and db-cAMP (cAMP mimetic) would 
improve resolution indices during acute pleurisy. 
In this self-resolving model of inflammation the 
intrapleural injection of LPS induces a time-
dependent influx of neutrophils into the pleural 
cavity of mice that is detectable at 2 h and 
reaches maximal at 8-24 h, decreasing thereafter 
with resolution occurring after 48hs, as 
previously reported (20,33,40,41). Therefore, we 
quantified the resolution interval (Ri) by defining 
profiles of acute inflammatory parameters 
(42,43). The treatment of mice with ROL or db-
cAMP at the peak of LPS-inflammation 
significantly reduced the number of PMN 
recruited to the pleural cavity and shortened Ri 
in ~ 12 hours (Fig. 1A and 1B).  
To investigate the potential relationship 
between cAMP and AnxA1, we carried out 
Western blot analysis in whole cell extracts 
recovered from the pleural cavity of mice treated 
4 h after LPS challenge (when inflammatory cell 
influx was already established). Western blot 
was performed to quantify the overall AnxA1 
content (ie. the sum of intracellularly localized 
or cell surface-bound). As seen in Fig 1C and 
1D, treatment with ROL or db-cAMP decreased 
neutrophil numbers and increased levels of intact 
AnxA1 (Fig. 1E and 1F). AnxA1 was 
constitutively expressed on resident cells from 





































induced AnxA1 cleavage (as detected by 
presence of the 33 kDa breakdown product) and 
treatment with ROL or db-cAMP increased 
levels of intact AnxA1 (37 kDa form) and 
reduced AnxA1 cleavage in whole inflammatory 
extracts when compared to LPS.  
 Dexamethasone, used as an anti-
inflammatory control drug, promoted resolution 
of neutrophilic inflammation and increased 
AnxA1 expression, as previously shown (20). 
Interesting, ROL was able to decrease neutrophil 
numbers and increase intact levels of AnxA1 as 
early as 1 h after treatment (Supplementary Fig. 
1A and 1B).  
The N-terminal region of AnxA1 is the 
major effector portion responsible for the anti-
inflammatory action of the protein and its 
cleavage decreases the resolution-inducing 
effects of AnxA1 (10,44). Here, we observed 
that ROL partially decreased LPS-induced 
AnxA1 cleavage, as evidenced by the lower 
levels of the 33-kDa fragment when compared to 
LPS alone (Figure 1E). As AnxA1 can be 
cleaved by elastase in vivo, we evaluated 
whether inhibition of elastase activity by ROL 
could account for the observed effect. We found 
that ROL decreased LPS-induced elastase 
activity and expression in whole cell lysates 
recovered from pleural inflammatory cells 
(Supplementary Fig. 1C and 1D). The latter 
results suggest that ROL modulates AnxA1 
levels at least by reducing its degradation.  
 
 Regulation of AnxA1 expression and 
phosphorylation by cAMP in macrophages. 
AnxA1 is present in many differentiated cell 
types (human and murine) but is particularly 
abundant in neutrophils, eosinophils, 
macrophages and mast cells (2,6). Protein 
expression can be modulated through several 
mechanisms such as the mobilization of 
intracellular pool of the protein to exportation 
and secretion, increased phosphorylation (45) or 
both. To explore the mechanisms underlying the 
effect of cAMP elevating agents on AnxA1 
expression and localization, in vitro experiments 
using differentiated THP-1 cells, BMDMs and 
the murine macrophage cell line RAW264.7 
were carried out. THP-1 was used in this work to 
evaluate the expression of AnxA1, since it has 
been shown to be a suitable cell line to study 
AnxA1 modulation (45,46). In these 
experimental settings, Dexa treatment induced 
dose-dependent induction of AnxA1 expression 
(data not show). As shown in the Fig 2, 
treatment of THP-1 cells with ROL increased 
AnxA1 levels in a concentration- (Fig 2A) and 
time- (Fig 2C) dependent fashion. This 
modulatory property was also observed in 
BMDM and RAW264.7 cells (Supplementary 
Fig 2A-C). For more quantitative data, similar 
experiments were performed to quantify AnxA1 
message by qPCR. Significant increases in 
AnxA1 mRNA were observed in THP-1 cells 
treated with ROL, with optimal settings at 10 
μM and 6 hours incubation (Fig 2B and 2D, 
respectively). Interesting, ROL also increased 
the level of phosphorylated AnxA1 in THP-1 
cells (Fig 2E) and BMDMs (Supplementary Fig 
2A). In line with the ability of ROL to inhibit 
degradation and increase intracellular levels of 
cAMP, there was strong phosphorylation of the 
CRE-binding protein (CREB), which followed 
the same kinetics of AnxA1 expression (Fig 2A 
and 2C). In accordance with the requirement of 
cAMP levels to induce AnxA1 expression, a cell 
permeable cAMP (db-cAMP) induced AnxA1 
accumulation and phosphorylation (Fig 3A and 
3B). Densitometry data for both, AnxA1 and P-
AnxA1 were represented graphically (Fig 3C). 
We also measured the intracellular levels of 
cAMP in THP-1 cells after rolipram treatment 
(10µM) and we found an increase of 20% over 
basal levels, which return to the baseline 2h 
after. As expected for a cell permeable cAMP, 
db-cAMP greatly increased levels of 
intracellular cAMP 1h after cell treatment by 
150% over basal, decreasing thereafter but still 
remain high until 2h (85% of increase over basal 
levels). 
  Moreover, Forskolin, a direct activator 
of adenylate cyclase, was also able to increase 
AnxA1 levels (Fig 3D). Noteworthy, 
physiological cAMP-elevating compounds such 
as PGE2, norepinephrine and adenosine (36,47-
51) were able to increase AnxA1 protein levels, 
as shown in the Supplementary Fig 3A-C. 
Likewise, monobutyryladenosine cAMP (6MB-
cAMP), a membrane permeable analog of cAMP 
that activates protein kinase A and is resistant to 
degradation by phosphodiesterase, was able to 
increase AnxA1 accumulation as did db-cAMP 
(Supplementary Figure 3D). In contract, a naked 
cAMP or yet a cell-permeable cGMP analog (8-
br-cGMP) did not increase AnxA1 
accumulation, as analyzed by Western blot (See 
Supplementary Figure 3E). 
Taken together, the data gathered so far 
suggested that ROL and other agents which 





































ways to regulate the dynamics of AnxA1 
accumulation: they increase mRNA expression, 
protein accumulation and phosphorylation of 
AnxA1. 
 
Rolipram and db-cAMP induce PKA-
dependent AnxA1 expression. The promoter 
region of the AnxA1 gene contains one cAMP-
responsive element (CRE) and this is functional 
since a CRE-binding protein (CREB) is required 
for either Dexa-induced or cAMP-induced 
AnxA1 synthesis (8,52). To investigate whether 
the observed effects of ROL occurred via PKA, 
the best-known cAMP downstream effector, 
THP-1 differentiated macrophages were treated 
with two PKA inhibitors, H89 (nonselective) or 
cAMPS-Rp (highly selective), 30 min before 
ROL or db-cAMP treatments. As shown in 
Supplementary Figure 4A-C, the blockade of 
PKA with H89 or cAMPS-Rp decreased AnxA1 
mRNA and protein levels induced by both ROL 
and db-cAMP. Of note, the effect of PKA 
inhibitors on ROL-induced AnxA1 levels was 
also observed in RAW264.7 murine 
macrophages (Supplementary Fig 2C).  
Since AnxA1 expression was associated 
to the proresolving role of cAMP (Fig 1) and the 
expression of AnxA1 in vitro was modulated via 
PKA (Supplementary Fig 2C and 4), we 
investigated if such pathway could also be 
engaged in vivo. In agreement with the in vitro 
findings, inhibition of PKA by H89 prevented 
ROL and db-cAMP-induced resolution of 
neutrophilic inflammation (Fig 4A and 4B) and 
this effect was associated with reduction of 
intact AnxA1 and increase of the cleaved form 
(Fig 4C and 4D).  
  
A nonselective FPR antagonist prevents 
rolipram and db-cAMP-induced resolution of 
neutrophilic inflammation. FPR2/ALX, a G 
protein-coupled member of the formyl peptide 
receptor (FPR) family, conveys the biological 
functions of a variety of ligands, including the 
proresolving mediators AnxA1 and lipoxin A4 
(9). To investigate whether there was 
involvement of these receptors in our system, we 
used the non-selective antagonist BOC-1, which 
blocks also FPR1. Administration of BOC-1, 
before ROL or db-cAMP injection, prevented 
resolution of inflammation induced by these 
cAMP-elevating agents (Fig 5A and 5B) as seen 
by permanence of neutrophil and decreased 
apoptosis into the pleural cavity. Apoptosis was 
evaluated biochemically through Mcl-1 - the 
most important Bcl-2 family protein that governs 
neutrophil half-life (53,54) - (Fig 5C and 5D) 
and AnnexinV staining (Fig 5F) or by 
morphological criteria (Fig 5E). Mcl-1 is a key 
anti-apoptotic protein of the Bcl-2 family protein 
known to be modulated by ROL (33).  Of note, 
treatment of mice with BOC-1 alone had no 
effect on neutrophil counts (data not show) and 
apoptosis (Fig 5E and 5F).  Prevention of ROL-
induced apoptosis by BOC-1 was associated 
with decreased levels of intact AnxA1 paralleled 
by increase of the cleaved form in cells from 
pleural exudates (Fig 5C and 5D).  
 
Neutralization of endogenous AnxA1 
prevents rolipram and db-cAMP-induced 
resolution of neutrophilic inflammation.  Having 
established the effect of AnxA1 receptor 
blockade on ROL and db-cAMP-induced 
resolution (Fig 5), we evaluated the effects of an 
anti-AnxA1 neutralizing strategy by using a 
specific antiserum. The administration of the 
anti-AnxA1 antiserum prevented ROL-induced 
resolution (Fig 6A) and apoptosis, as assessed 
using either morphological criteria (Fig 6B and 
6E) or biochemically by Mcl-1 (Fig 6C) and 
Annexin V staining (Fig 6D). Of note, treatment 
of mice with a goat nonimmune serum had no 
effect on the resolution of LPS-induced pleurisy 
(data not show) reinforcing previous report (20). 
AnxA1 neutralization was also able to prevent 
the effect of db-cAMP on neutrophil numbers 
(Fig 7A) and apoptosis (Fig 7B-E) similarly to 
the results obtained with ROL.   
Furthermore, we carried out experiments 
using AnxA1 deficient mouse (24) and found 
results similar to those obtained by inhibition of 
AnxA1 actions with BOC-1 or AnxA1 
neutralization. Indeed, the treatment with ROL 
or db-cAMP was able to induce neutrophil 
apoptosis in WT mice, and such an effect was 
impaired in AnxA KO mice (Fig 8). Therefore, 
we have shown by pharmacological and genetic 
strategies the importance of AnxA1 for the 
proresolving properties of ROL and db-cAMP. 
 
Rolipram and db-cAMP override the 
survival-inducing effect of LPS in human 
neutrophils and such an effect is Anxa1 
dependent. Neutrophil apoptosis is an integral 
modulatory mechanism that constrains 
inflammation and contributes to its successful 
resolution. The fate of neutrophils inside an 
inflammatory milieu - ie. whether they  undergo 





































balance of  pro-survival stimuli such LPS, GM-
CSF and oxygen availability, as well as the 
presence of pro-apoptotic stimuli including Fas 
ligand and TNF (55). Because ROL and db-
cAMP induced neutrophil apoptosis in an 
inflammatory milieu in vivo, we investigated the 
ability of these cAMP elevating agents to 
counteract the prosurvival effects of LPS in 
vitro. As previously showed, LPS decreased the 
spontaneous apoptosis of cultured human 
neutrophils (41) and the treatment with ROL and 
db-cAMP prevented this effect, as evaluated by 
increased percentage of apoptotic neutrophils 
when comparing LPS-treated cells with 
LPS+ROL or LPS+db-cAMP (Fig 9A and 9G). 
There was no difference among the different 
doses used (Fig 9B and 9C). Sivelestat, a 
synthetic protease inhibitor, was used as a 
positive control for induction of neutrophil 
apoptosis (Fig 9A), as previously reported (41). 
In accordance with our in vivo data, the ability of 
ROL and db-cAMP to decrease the prosurvival 
effect of LPS was abolished by pretreatment 
with Anti-AnxA1 serum (Fig 9D and 9E) or by 
using WRW4, a selective FPR2 antagonist (Fig 
9F). Therefore, our data show that cAMP 
elevating agents can effectively induce or 
accelerate a pro-apoptotic program in 





Cyclic AMP is a fundamental second-
messenger-molecule produced after adenylate 
cyclase activation in response to several stimuli, 
endowed with fundamental modulatory activities 
in cells involved in the inflammatory process, a 
property exerted primarily through PKA activity. 
Intracellular levels of cAMP result from a 
balance of modulatory pathways that involve 
elevation through agonist ligands (such as PGE2, 
adenosine and β-adrenergic drugs) and 
degradation by phosphodiesterases (PDEs) 
(27,28,56). There are different families of PDEs 
with various roles in different cells or tissues. 
The PDE4 isoenzyme family plays a particularly 
important role in the immune system and is the 
predominant PDE in inflammatory cells 
including mast cells, eosinophils, neutrophils, T 
cells and macrophages (56). Our group has 
previously shown that ROL and cAMP mimetics 
induce resolution of an established neutrophilic 
or eosinophilic inflammation (32,33) by 
inducing caspase-dependent apoptosis of 
polymorphonuclear cells.  
In this follow up study, we reveal an 
important role for AnxA1 in the proresolving 
properties of ROL and db-cAMP, the cyclic 
AMP mimetic of choice. This conclusion is 
substantiated by the following major findings: (i) 
ROL and db-cAMP promoted resolution in a 
model of acute inflammation in mice challenged 
with LPS, and this process was associated with 
increased levels of intact AnxA1; (ii) ROL 
induced AnxA1 expression and phosphorylation 
in macrophages, an effect associated to CREB 
phosphorylation. Dibutyryl-cAMP, forskolin and 
physiological cAMP-elevating agents increased 
AnxA1 expression; (iii) The increase of AnxA1 
induced by ROL was PKA-dependent in human 
(THP-1) and murine (RAW) macrophages; (iv) 
The effect of ROL and db-cAMP in vivo was via 
PKA as shown by using PKA inhibitors. The 
latter drugs not only prevented cAMP-induced 
resolution, but also prevented the increase in 
intact AnxA1 levels; (v) Two different 
pharmacological strategies were employed to 
inhibit the AnxA1 pathway, FPR antagonism 
and neutralizing AnxA1 antiserum: in both cases 
there was marked reduction of the resolution 
properties displayed by cAMP elevating agents. 
Importantly, in AnxA1 deficient mice, ROL or 
db-cAMP treatment could not induce neutrophil 
apoptosis. (vi) ROL and db-cAMP induced 
AnxA1-dependent apoptosis of human 
neutrophil in presence of prosurvival stimuli 
LPS. Therefore, our results show that the effects 
of ROL and db-cAMP on resolution of 
inflammation are at least in part due to 
modulation of AnxA1 expression, stabilization 
and mobilization to cell surface. These data 
identify AnxA1 as a proresolving molecule 
involved in pro-resolving actions of cAMP  (Fig 
10).  
In addition to the role of AnxA1 in 
mediating anti-inflammatory properties of 
endogenous cortisol, AnxA1 is also an important 
mediator of anti-inflammatory and proresolving 
properties of pharmacological doses of 
glucocorticoids (20,57). During the initial steps 
of acute inflammation, AnxA1 limits the 
recruitment of leukocytes and the production of 
pro-inflammatory mediators (2). During the 
resolution phase, AnxA1 acts by promoting the 
apoptosis of neutrophils (10,20) and increasing 
their efferocytosis by macrophages (10,21). 
Recent studies indicate that modulation of 





































externalization in specific cell targets may 
represent a common mechanism evoked by anti-
inflammatory agents, such as LXA4 (58) and 
oestrogens (59). Interestingly, in this study we 
have found that physiological cAMP-elevating 
compounds such as adenosine increase AnxA1 
protein levels. However, remain to be 
investigated whether AnxA1 account for the 
proresolving abilities of adenosine and 
which receptor is engaged to elicit this 
effect. Another group of drugs, HDAC 
inhibitors, endowed with multiple properties like 
the PDE4 inhibitor used here, also modulate 
AnxA1 expression and localization. Indeed, 
administration of HDAC inhibitors such as 
valproic acid and sodium butyrate at the peak of 
zymosan-induced peritonitis accelerated 
resolution in wild type mice, but much more 
modestly in AnxA1 null mice. These effects 
were consequence of the capacity of HDAC 
inhibitors to elevate AnxA1 levels, which then 
modulated leukocyte apoptosis and efferocytosis 
(24). During the resolving phase of LPS-
inflammation, high levels of AnxA1 have been 
found in macrophages with resolutive 
phenotypes (40). 
Phosphorylation and release of AnxA1 
are central to the mechanism of action of the 
antiallergic cromoglycate-like drugs on mast 
cells and are essential for the inhibition of the 
release of histamine and PGD2. The latter effects 
were abolished in the presence of neutralising 
anti-AnxA1 monoclonal antibody (6). In our 
studies, we demonstrated that ROL and db-
cAMP promoted resolution of neutrophilic 
inflammation associated to high levels of intact 
AnxA1 and decreased levels of the cleaved 
form. Furthermore, ROL induced AnxA1 mRNA 
expression, accumulation and phosphorylation in 
macrophage lineages. More importantly, the 
blockage of the endogenous AnxA1 prevented 
the proresolving effects of these cAMP elevating 
agents and ROL and db-cAMP prevented the 
prosurvival effect of LPS on human neutrophils.  
 cAMP regulates apoptosis in several cell 
types, inhibiting or stimulating the process 
depending on the cell type and stage of 
differentiation (60). There are some in vitro 
studies using neutrophils that have shown that 
PDE4 inhibition or an increase of cAMP levels 
by other cAMP-increasing agents delay 
neutrophil apoptosis (61-64). In contrast with 
these in vitro studies, our group demonstrated 
that in vivo administration of ROL was clearly 
associated with resolution of neutrophilic 
inflammation by inducing caspase-3-dependent 
apoptosis (33). It is important to point out that 
our experimental settings were designed to 
investigate if these drugs could interfere with 
neutrophil accumulation (apoptosis+ 
efferocytosis/clearance) and not infiltration 
(migration), since we treated mice 4 h after LPS 
challenge, when inflammatory cell influx was 
already established. Indeed, we have previously 
shown that the neutrophil-active chemokines, 
such as CXCL1 and CXCL2 peak early in this 
model of inflammation (1-2h) and their levels 
are similar to basal at 4h after LPS injection 
(33). Also, injection of reparixin (an allosteric 
inhibitor of CXCR2) 4h-after LPS challenge 
failed to affect the accumulation of neutrophils, 
while in the same experiment, post-treatment 
with rolipram greatly decreased neutrophil 
accumulation in the cavity. Therefore, the effects 
of ROL and db-cAMP in our experimental 
settings  are not in the migration process of the 
cells into the pleural cavity, since the cAMP 
elevating agents were given after the stimulus 
and after the peak of neutrophil-active 
chemokine production in the cavity (33).  
Here, we went further and clearly 
showed that cAMP-elevating agents were able to 
induce AnxA1-dependent resolution of 
inflammation and increased neutrophil apoptosis 
associated with loss of Mcl-1. Importantly, the 
blockage of AnxA1 pathway prevented Mcl-1 
loss and it was associated to neutrophil survival. 
The apoptotic effect of ROL and db-cAMP was 
also observed in cultured human neutrophils 
exposed to the prosurvival stimuli of LPS. The 
apparent contradictory actions of cAMP on 
isolated neutrophils of the previous studies (61-
64) with our study can be explained because 
ROL and db-cAMP induce apoptosis in the 
presence of an inflammatory milieu, when these 
drugs were able to counteract the prosurvival 
stimuli such as LPS. These data presented here 
cluster with those generated with HDAC 
inhibitors and cromoglycate-like drugs to 
suggest that induction of AnxA1 may account 
for the anti-inflammatory and resolving 
mechanisms of a few known drugs. We propose 
that AnxA1 represents a central check-point 
mechanism regulating leukocyte survival and 
reactivity during on-going inflammatory 
reactions. 
After cell activation, AnxA1 is 
externalized on the cell surface, the N-terminal 
region is exposed and interacts with its receptor 





































medium, AnxA1 can to be cleaved at the N-
terminal region by proteases including NE and 
PR3, generating the 33-kDa isoform of poorly 
known properties. Intact AnxA1 (37 kDa) is the 
biological active form of the protein (13,44,65). 
Here, we showed that compounds which we 
have previously show to increase resolution of 
neutrophilic inflammation (33), are able to 
increase the levels of intact AnxA1 and prevent 
partially its degradation. A recent work of our 
group (66) showed that ROL could increase 
intact AnxA1 and prevent AnxA1 cleavage 
associated to ameliorated of inflammation of 
pneumococcal pneumonia.  Interestingly, such 
an effect was more efficient when ROL was 
combined with the antibiotic ceftriaxone. 
Therefore, the effect of ROL on the cleaved 
levels of AnxA1 may be, at least in part, due to 
the decreased elastase activity and expression, 
and associated with decreased neutrophils 
number since elastase is an important protease 
present in neutrophils. In the inflammatory 
context, the decreased elastase levels may be 
important to resolution occurs. During the 
resolving phase of LPS-induced inflammation, 
in which was associated with decreased elastase 
expression and activity there were more intact 
AnxA1. Conversely, during the productive phase 
of inflammation there were high elastase 
expression/activity and higher proportion of 
AnxA1 cleavage. Indeed, inhibition of elastase 
by using synthetic (Sivelestat) or natural 
inhibitors (elafin or secretory leukocyte protease 
inhibitor - SLPI) was able to promote resolution 
of inflammation by protection of endogenous 
intact levels of AnxA1 and resulting neutrophil 
apoptosis (13,41,65). Furthermore, cleavage-
resistant (CR) AnxA1 exhibited greater anti-
inflammatory effect when compared with the 
parent protein in different animal models of 
inflammation (13,41,65). 
The regulation of cAMP levels is a key 
feature to regulate a large number of events in 
the body (67). As a ubiquitous second 
messenger, cAMP regulates several processes in 
many cell types including cells from the immune 
system (30-32,34,35). Elevated cAMP levels 
were reported at the resolution point in a model 
of resolving peritonitis, and this was important 
to clear PMNs and regulate monocyte-derived 
macrophage functions (31). Sokolowska and 
colleagues (36) demonstrated that prostaglandin 
E2, a potent lipid mediator involved in 
maintaining homeostasis, inhibits NLRP3 
inflammasome activation through EPE4 receptor 
and an increase in intracellular cAMP in human 
macrophages. In teleost fish, prostaglandin E2 
promoted M2 polarization macrophages via a 
cAMP/CREB signaling pathway (37). Bystrom 
and colleagues (30) examined whether 
macrophage phenotype was dictated by cAMP 
and whether this phenotype could be altered by 
changing intracellular levels of this potent 
intracellular second messenger. In M1 
macrophages, TNFα production was attenuated 
by db-cAMP, whereas IL-10 production was 
increased, suggesting a reversion toward the 
anti-inflammatory or resolutive phenotype. 
Noteworthy, cAMP may function as an 
intermediate of the effects of other pro-resolving 
molecules, such as melanocortins peptides (38), 
lysophosphatidylserine (39) and resolving D1 
(RvD1) (68,69). Recently it was reported the 
effect of cAMP on neutrophil extracellular trap 
(NET). Shishikura and colleagues have 
described the inhibitory action of PGE2 on 
PMA-induced NET formation in vitro through 
EP2 and EP4 Gαs-coupled receptors. Also, 
incubation with db-cAMP or inhibitors of PDE, 
also suppressed NET formation (70). Here, we 
described one more immunomodulatory function 
for cAMP, induction of AnxA1-dependent 
resolution of inflammation.     
The biology of cAMP is mediated by 
downstream effector molecules and the most 
important one is protein kinase A (PKA): cAMP 
binds directly to PKA provoking a functional re-
arrangement with enzymatic activity. PKA was 
shown to mediate, for example, the inhibition on 
macrophage inflammatory mediator generation 
induced by cAMP (71), and according to (32), 
the inhibition of PKA by H89 was able to limit 
the cAMP-mediated neutrophilic resolution. 
EPAC is another protein that, together with 
PKA, is the major binding partner of cAMP 
(72). In our model we investigated whether 
inhibition of PKA with H89 could inhibit the 
resolution induced by ROL and db-cAMP. In 
agreement with these previous studies, H89 
reverted resolution induced by both ROL and 
db-cAMP in vivo and these events were followed 
by a decrease in the levels of intact AnxA1. 
Moreover, our in vitro experiments confirmed 
the non-redundant function of PKA since pre-
treatment with H89 or a more selective cAMP-
Rp thethylammonium, reduced cellular levels of 
AnxA1 below those measured in RAW264.7 or 
THP-1 cells treated with ROL alone. When this 
antagonist is used, the levels of AnxA1 are 





































cAMP to the action of ROL in this system. 
Altogether, these experiments led us to conclude 
that PKA is the major effector for cAMP in the 
processes evoked by ROL.  
Obviously, by interfering with cAMP 
levels we may alter cGMP levels (because some 
PDEs hydrolyse both cAMP and cGMP, so 
PDEs that metabolize cGMP may be altered by 
intracellular cAMP levels) (73,74). In this sense, 
it will be import in the future to study the cross 
talk between cAMP and cGMP. 
In conclusion, our study showed that 
cAMP elevating agents increase levels of 
AnxA1 and this is functionally involved in the 
pro-resolving abilities of cAMP. These results 
reinforce the hypothesis that AnxA1 acts at 
multiple regulatory levels to promote resolution 
of inflammation and may be a common 
mechanism that account for the pro-resolving 
actions of pro-resolving molecules. cAMP 
elevating drugs may represent a useful 
therapeutic strategy not only to block 
inflammatory processes (during onset of 
inflammation) but also, and equally important, to 
actively induce the mechanisms underlying the 




Animals. Male BALB/c mice (8-10 weeks) 
obtained from the Bioscience Unit of Instituto de 
Ciências Biológicas (Brazil) were housed under 
standard conditions of optimum light, 
temperature and humidity (12:12 h light–dark 
cycle, 22 ± 1°C, 50–60%) with food and water 
provided ad libitum. Annexin A1 knockout 
(BALB/c background) mice were generated as 
previously described (57) and bred at the 
Universidade Federal de Minas Gerais. All 
described procedures had prior approval from 
the Animal Ethics Committee of Universidade 
Federal de Minas Gerais (CEUA/UFMG, 
protocol number 15/2011). 
 
Drugs, reagents and antibodies. 
Dibutyryl cAMP (db-cAMP), 6MB-cAMP, 
cAMP, Forskolin, Dexamethasone, Adenosine, 
(-)-norepinephrine, sodium butyrate, cGMP, 
Anti-β-actin (#A5316) and LPS (from 
Escherichia coli serotype O:111:B4) were from 
Sigma Aldrich (St. Louis, MO, USA). 8-Br-
cGMP was from Calbiochem (EMD chemicals, 
San Diego, CA). Rolipram was purchased from 
Enzo Life Science (NY, USA). H89 
dihydrochloride and cAMPS-Rp 
trethylammoniun salt were from Tocris 
(Ellisville, MO, USA). Prostaglandin E2 (PGE2) 
was from Cayman Chemical (Michigan, USA). 
Anti-AnxA1 antiserum was a king gift from Dr. 
Steve Poole (Biotherapeutics Group, National 
Institute for Biological Standards and Control, 
UK). Anti-AnxA1 (Sc-11387), anti-elastase (Sc-
9521) or secondary anti-mouse (Sc-2005) 
peroxidase-conjugate antibody were purchased 
from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). Anti P-CREB (#9191) and secondary 
anti-rabbit peroxidase-conjugate antibody 
(#7074) were from Cell Signaling Technology 
(Danvers, MA, USA). We also used Anti-
AnxA1 (#713400) from Invitrogen (Carlsbad, 
CA, USA). BOC-1 (N-t-Boc-Met-Leu-Phe) was 
from MP Biomedicals (California, USA). 
Polyclonal anti-Ser27-AnxA1 antibody was 
generated as previously described (75). 
 
LPS-induced pleurisy model and 
treatment with drugs. Mice received an 
intrapleural (i.pl.) injection of LPS (250 
ng/cavity) or phosphate-buffered saline (PBS) as 
previously described (20,33). Four hours later, 
mice were treated with rolipram (6 mg/kg, i.p.), 
Dexa (2 mg/kg, i.p.) or with db-cAMP (4 mg/kg, 
i.pl.). These doses and route of administration 
were validated in our previous studies (20,32). 
AnxA1-knockout mice were also treated with 
these drug doses. To prevent the action of 
AnxA1, mice were treated with BOC-1, a 
nonselective AnxA1 receptor antagonist (5 
mg/kg, i.p.) 30 min before the drugs or with anti-
AnxA1 antiserum (0.1 mL hyperimmune serum 
diluted in 100 µL PBS/mice, i.p.) given 1 h 
before the challenge with LPS and again 1 h 
before ROL. In other cases, the PKA inhibitor 
H89 (4 mg/kg, i.pl.) was used. Compounds were 
diluted in DMSO or ethanol and further in PBS. 
db-cAMP was only diluted in PBS. Control mice 
received the respective vehicle only. Mice were 
euthanized by inhalation of CO2. Cells in the 
pleural cavity were harvested by washing the 
cavity with 2 mL of PBS and total cell counts 
performed in a modified Neubauer chamber 
using Turk’s stain. Differential cell counts were 
performed on cytocentrifuge preparations 
(Shandon Cytospin III) and the slides were 
stained with May-Grünwald-Giemsa using 
standard morphological criteria to identify cell 
types (20,33,57). Results are presented as the 






































Calculation of resolution indices. We 
quantified the resolution indices as previously 
described (42,43). Murine pleural exudates were 
collected at 8, 24, 36 and 48 time points after 
LPS challenge. The number of PMN and 
mononuclear cells was determined by total and 
differential leukocyte counting. The resolution 
of acute inflammation was defined in 
quantitative terms by the following resolution 
indices: 1) magnitude (ψmax and Tmax), ψmax (the 
maximal PMN numbers in the exudates), 
Tmax (time point when PMN numbers reach 
maximum); 2) duration (T50), T50 (time point 
when PMN numbers reduce to 50% of 
maximum) and 3) resolution interval Ri (the time 
period when 50% PMNs are lost from the 
pleural cavity, i.e., T50 -Tmax). 
 
Cell culture and in vitro assays. The 
human promonocytoid cell line THP-1 and 
murine macrophages RAW264.7 were obtained 
from the American Type Culture Collection 
(ATCC, Rockville, MD, USA). THP-1 cells 
were cultured in RPMI 1640 medium (Cultilab, 
São Paulo, Brazil) supplemented with 8% heat-
inactivated fetal bovine serum (FBS) and 
antibiotics (Cultilab, São Paulo, Brazil) and 
RAW264.7 cells were cultured in DMEM 
(Cultilab, São Paulo, Brazil) in the same 
conditions. Cell cultures were maintained at 
37˚C and 5% CO2, and cell viability was deter-
mined using a trypan blue dye-exclusion assay. 
THP-1 cells were differentiated using 4α-
phorbol 12-myristate 13-acetate (PMA - 20 
ηg/mL, Sigma Aldrich, St. Louis, MO, USA) 
and deprived with FBS 1% for 24 h; 
subsequently cells were treated with drugs at 
different time intervals and concentrations as 
indicated in the specific figures. Dexamethasone 
(Dexa) was used as a positive control for AnxA1 
induction. 
cAMP measurements. cAMP levels in 
cellular extracts were measure using the cAMP 
Direct Immunoassay Kit, as described by the 
manufacturer (Cat#ab65355 Abcam, Cambridge, 
UK). Briefly, THP-1 cells were lysed completely 
with 0,1M HCl, following by centrifuging 10.000 
RPM for 10 min. The supernatant was 
collected as the testing sample. To be ready for 
quantification, cAMP standards and samples 
were neutralized and acetylated using the 
neutralizing buffer and acetylating reagent 
supplied in the Kit, respectively. During the 
quantification, standard cAMP and testing 
samples were added to the Protein G coated 96-
well plate. After blended with anti-
cAMP antibody, the suspension was incubated 
for 1 h at room temperature with gentle agitation 
and for another hour with the adding of cAMP-
HRP. Then the plate was washed for five times, 
following by incubation with HRP developer for 
1 h. The reaction was stopped by 1M HCl and the 
absorbance was detected by a microtiter plate 
reader (Spectra Max 190, Molecular Devices) at 
450 nm. The molar concentration of cAMP in 
cells was determined from standard curves 
generated using standard preparation. The 
cAMP levels were expressed by percentage 
above the control untreated cells.   
 
Bone-marrow derived macrophages 
(BMDMs). Bone marrow cell suspensions 
were isolated by flushing femurs and tibias 
of 8-10 week BALB/c mice with complete 
DMEM (+10% FCS, + 1% Pen/Strep) and 
20% L929 cell-conditioned medium 
(LCCM) as a source of macrophage colony-
stimulating factor (M-CSF) (76). Aggregates 
were dislodged by gentle pipetting, and 
debris was removed by passaging the 
suspension through a cell strainer (BD 
Biosciences). Cells were seeded on 6-well 
plates and incubated at 37°C in a 5% CO2 
atmosphere. Five days after seeding, another 
2 ml of DMEM containing 10% FBS and 
20% LCCM was added. On the seventh day, 
cells were completely differentiated into 
macrophages. Cells were seeded on 24-well 
plates (5 x 105 cells/well) and later were pre 
incubated with rolipram (10 µM) for one 
hour and further stimulated with LPS (100 
ng/mL) for 24 hours. 
 
In vitro assay to evaluate neutrophil 
apoptosis. Neutrophils were isolated from 
human peripheral blood from healthy donors 
(Ethics Committee of the Universidade Federal 
de Minas Gerais, Brazil - Institutional Review 
Board Project number 0319.0.203.000-11) by 
using histopaque gradient (Histopaque 1119 and 
1077 - from Sigma Chemicals, St. Louis, MO, 
USA) as described previously (41,77). 
Neutrophils (1 x 106 cells/well) were 
resuspended in RPMI 1640 medium, seeded in 
96-well culture plates (BD Biosciences) and 
incubated at 37°C in a 5% CO2 atmosphere. Cell 
viability was determined using a trypan blue 





































preparations was 95%. To evaluate the effect of 
ROL or db-cAMP on LPS-induced 
prosurvival/delayed apoptosis of neutrophils, 
isolated neutrophils were cultured in the 
presence of LPS (500 ng/mL) and 1 h after were 
treated with the drugs for further 5 h as indicated 
in the figures. In some experiments, neutrophils 
were pre-treated with an anti-AnxA1 antiserum 
(αAnxA1 - 100 μg/mL) or a selective antagonist 
of FPR2, WRW4 - 10 μM (number 344220; 
Calbiochem, San Diego, CA, USA) before 
addiction of LPS. Sivelestat - 100 μg/mL 
(number S7198; Sigma-Aldrich, St. Louis, MO, 
USA) was used as a positive control for 
neutrophil apoptosis (41). Apoptosis was 
evaluated morphologically (as described above) 
and the experiments were performed in 
biological quadruplicates.  
 
Assessment of leukocyte apoptosis. 
Apoptosis was assessed as previously reported 
(20,33). Briefly, cells (5 x 104) collected after 
LPS challenge or from in vitro experiments were 
cyto-centrifuged, fixed and stained with May-
Grünwald-Giemsa and counted using oil 
immersion microscopy (x100 objective) to 
determine the proportion of cells with distinctive 
apoptotic morphology (cells with chromatin 
condensation, nuclear fragmentation and 
formation of apoptotic bodies out or inside 
macrophages). At least 500 cells were counted 
per slide and results are expressed as the mean ± 
SEM of percentage of cells with apoptotic 
morphology. Assessment of neutrophil  
apoptosis (Ly6G+/F4/80-/AnxV+/7AAD-) was 
also performed by flow cytometry using FITC-
labeled annexin V and 7- aminoactinomycin D 
(BD Biosciences, San Jose, CA, USA) as 
previously reported (40,41). Antibodies used 
were F4/80 (PEcy7; eBioscience, San Diego, 
CA, USA) and Ly6G (V450; BD Bioscience, 
San Jose, CA, USA). Stained cells were acquired 
in BD FACSCanto II cell analyzer (BD 
Biosciences) and analyzed using FlowJo 
software (Tree Star, Ashland, OR). 
 
Western blot analysis. Inflammatory 
cells harvested from the pleural cavity, THP-1, 
RAW264.7 or BMDMs were washed with PBS 
and whole cell extracts were prepared as 
described (32,78,79). The protein content of the 
lysate was determined by Bradford assay reagent 
(Bio-Rad, Hercules, CA, USA). Extracts (20 µg) 
were separated by electrophoresis on 10% SDS-
PAGE and electrotransferred to nitrocellulose 
membranes, as described (78). Membranes were 
blocked overnight at 4°C with PBS containing 
5% (w/v) nonfat dry milk and 0.1% Tween-20, 
washed three times with PBS containing 0.1% 
Tween-20 and then incubated with anti-AnxA1 
(Santa Cruz, 1:1000 or Invitrogen, 1:3000), 
polyclonal anti-Ser27-AnxA1 (1:1000), anti-P-
CREB (1:1000), anti-Mcl-1 (1:1000), anti-
elastase (1:1000) and anti-β-actin (1:5000) 
antibodies in PBS containing 5% (w/v) BSA and 
0.1% Tween-20. After washing, membranes 
were incubated with appropriated horseradish 
peroxidase-conjugated secondary antibody 
(1:3000). Immunoreactive bands were visualized 
by using an ECL detection system, as described 
by the manufacturer (GE Healthcare, 
Piscataway, NJ). The values of AnxA1 or P-
AnxA1 were quantified by using a densitometric 
analysis software (ImageJ, Image Processing and 
Analysis in Java; NIH, Bethesda, MD). Changes 
in protein levels were estimated by the control 
(untreated cells) and the results were expressed 
as fold increase of the arbitrary units of AnxA1 
or P-AnxA1 normalized to the values of β-actin 
in the same sample. 
 
RNA extraction and quantitative RT-
PCR. Total RNA was extracted using the 
RNeasy Mini Kit (Qiagen, Crawley, UK) 
according to the manufacturer’s instructions. 
cDNA was synthesized from 1 µg of RNA with 
SuperScript III Reverse Transcriptase 
(Invitrogen, Carlsbad, CA, USA), following the 
manufacturer’s recommended protocol. 
Synthesized cDNA was added to the relevant 
forward and reverse primer together with Power 
SYBR Green PCR Master Mix (Applied 
Biosystems, Warrington, UK). Real-time PCR 
was performed in duplicate, with 1 μL  cDNA at 
a concentration of 100 ng, 0.5 mM primers and 
Power SYBR Green PCR Master Mix (Applied 
Biosystems, Warrington, U.K.) using StepOne 
(Applied Biosystems, Foster City, CA, USA). 
The data were analyzed using StepOne 
Detection System software with a cycle 
threshold (Ct) in the linear range of 
amplification and then processed by the 2-ΔΔCt 
method. Reactions were run in duplicates. 











































the absence of unspecific products. Samples of 
all groups were run on one plate with two 
technical replicates. Gapdh was used as an 
endogenous control to normalize the variability 
in expression levels and results were expressed 
as fold increase. 
 
Elastase activity assay. The elastase 
activity was measured in cell extracts prepared 
in the absence of proteases inhibitors by using an 
in-house procedure that relies on the use of 
MeO-Suc-AA-Pro-Val-pNA (M4765-Sigma 
Aldrich, St. Louis, MO, USA) as substrate. Cells 
obtained from pleural cavity of mice were lysed 
on appropriated buffer (200 mM NaCl, 20 
mM Tris-HCl, 1% Triton X-100, pH 8.0). The 
lysate was centrifuged at 12.000 rpm in a 
microcentrifuge for 15 minutes at 4º C and 
supernatant (30 µL) was added to 20 µL of TBS 
(Tris-HCl, pH 8.0) and 50 µL of the substrate (1 
mM) in a 96-well microplate. Following 
incubation for 2 h at 37º C, the absorbance of 
samples was analyzed in a spectrophotometer 
(Spectra Max 190, Molecular Devices) at 405 
nm. A standard curve was performed with p-
nitroanilide in accordance to the procedures 
supplied by the manufacturer (BioVision Inc., 
California, USA). The results are presented as 
elastase activity absorbance. 
 
Statistical analysis. All results are 
presented as the mean ± SEM. Data were 
analyzed by One-way ANOVA, and differences 
between groups were assessed using the Student-
Newman-Keuls post-test. A P value < 0.05 was 
considered significant. Calculations were 
performed using the Prism 5.0 software for 
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Figure 1. Effect of the treatment with rolipram and db-cAMP on resolution of acute 
inflammation. Evaluation of resolution indices: mice were injected with LPS (250 ng/cavity, i.pl.) or 
PBS and 8 h later received an injection of ROL (6 mg/kg, i.p.) or db-cAMP (4 mg/kg, i.pl.). Pleural 
wash were performed at various time points after LPS injection and neutrophils were count from 
cytospin preparations (A) to calculate resolution indices (B). In C-F, mice were injected with LPS 
(250 ng/cavity, i.pl.) or PBS and 4 h later received an injection of ROL or db-cAMP at the same dose 
of A, or Dexa (2 mg/kg, i.p.) as a control. The cells from pleural cavity were harvested and processed 
for neutrophils count (C, D) and western blot analysis (E, F) for detection of AnxA1 4 h later drug 
treatment, i.e., 8 h later LPS-challenge. Two different exposures time of the cleaved band of AnxA1 
immunoblot are presented. Results are expressed as number of neutrophils/cavity and are shown as 
the mean ± SEM of at least five mice in each group. ***P < 0.001 when compared with PBS-injected 
mice; ##P < 0.01 or ###P < 0.001 when compared with LPS-challenged mice. For loading control, 
membranes were reprobed with anti-β-actin. Blots are representative of three independent experiments 
using pooled cells from at least five animals in each experiment. 
 
Figure 2. Effect of rolipram on AnxA1 mRNA expression, protein levels and phosphorylation in 
THP-1 differentiated macrophages. Cells were differentiated using PMA (20 ng/mL) and serum 
deprived for 24 h. Later, the cells were untreated or treated with ROL at increasing concentrations for 
6 h (A, B, E), or different time intervals (C, D, E) as indicated in the Figure. Whole cell extracts were 
obtained and subjected to Western blot analysis (A, C, E) to assess for AnxA1, Ser27-phospho-AnxA1, 
and Phospho-CREB levels (as a marker of PKA activation) or for quantitative RT-PCR (B, D). For 
loading control, membranes were reprobed with anti-β-actin. Blots are representative of three 
independent experiments. qRT-PCR data were performed in biological triplicates performed with two 
technical replicates. The results are presented as fold increase of mRNA expression relative to the 
amount present in control samples. Data are mean ± SEM. **P < 0.01 and ***P < 0.001, when 
compared to untreated cells; ###P < 0.001 when compared to ROL treatment at 10 µM or 6 h.  
 
Figure 3. Effect of db-cAMP and Forskolin on AnxA1 expression and phosphorylation in THP-1 
differentiated macrophages. Cells were differentiated using PMA (20 ng/mL) and serum deprived 
for 24 h. After starvation, the cells were untreated or treated with db-cAMP (A, B) or Forskolin (D) at 
different concentrations (6 h) and times as indicated in the Figures. Total cell extracts were obtained 
and subjected to Western blot analysis to assess for AnxA1 (A, B, D) or Ser27-phospho-AnxA1 (A). 
Densitometry data are presented graphically in the panel C. For loading control, membranes were 
reprobed with anti-β-actin. Blots are representative of three independent experiments. Data are mean ± 
SEM. *P < 0.05, **P < 0.01 and ***P < 0.001, when compared to untreated cells.  
 
Figure 4. Rolipram and db-cAMP resolve neutrophilic inflammation in a PKA-dependent 
manner. Mice were injected with LPS (250 ng/cavity, i.pl.) or PBS and 4 h later received an injection 
of ROL (6 mg/kg, i.p.) or db-cAMP (4 mg/kg, i.pl.). Two groups of mice were pre-treated 30 min 
with H89 (4 mg/kg, i.pl.) before the drugs. The cells from pleural cavity were harvested and processed 
to neutrophils count (A, B) and western blot (C, D) for detection of AnxA1 4 h after drug treatment, 
i.e., 8 h after LPS challenge. Two different exposures time of the cleaved band of AnxA1 immunoblot 
are presented. Results are expressed as the number of neutrophils/cavity and are shown as the mean ± 
SEM of at least five mice in each group. ***P < 0.001 when compared to PBS-injected mice; #P < 
0.05 and ##P < 0.01 when compared to LPS-challenged mice. Comparison between the groups H89 
and H89+drugs are highlighted in the graphics. For loading control, membranes were reprobed with 
anti-β-actin. Blots are representative of three independent experiments in pools of cells from at least 
five animals in each experiment. 
 
Figure 5. Effect of treatment with BOC-1, a FPR/ALX antagonist, on ROL and db-cAMP-
induced resolution of acute inflammation. Mice were injected with LPS (250 ng/cavity, i.pl.) or 
PBS and 4 h later received an injection of ROL (6 mg/kg, i.p.) or db-cAMP (4 mg/kg, i.pl.). An 





































were harvested and processed to neutrophils count (A, B) and western blot analysis (C, D) for 
detection of AnxA1 and Mcl-1, 4 h later drug treatment, i.e., 8 h later LPS challenge. Two different 
exposures time of the cleaved band of AnxA1 immunoblot are presented. Number of apoptotic 
neutrophils was determined morphologically (E) and by flow cytometry of Annexin V+ neutrophils 
(F) 24 h after LPS injection. Results are expressed as the number of neutrophils/cavity (A, B), 
percentage of neutrophils with apoptotic morphology (E) and number of apoptotic neutrophils 
(Ly6G+/F4/80-/AnxAV+/7AAD-) (F), and are shown as the mean ± SEM of at least five mice in each 
group. *P < 0.05 or ***P < 0.001 when compared with PBS-injected mice; #P < 0.05, ##P <0.01 or 
###P < 0.001, when compared with LPS-challenged mice. Comparison between the groups BOC and 
BOC+drugs are highlighted in the graphics. For loading control, membranes were reprobed with anti-
β-actin. Blots are representative of three independent experiments using pooled cells from at least five 
animals in each experiment. 
 
Figure 6. Effect of treatment with anti-AnxA1 antiserum on ROL-induced resolution of acute 
inflammation. Mice were injected with LPS (250 ng/cavity, i.pl.) or PBS and 4 h later received an 
injection of ROL (6 mg/kg, i.p.). Injections of anti-AnxA1 antiserum (αAnxA1, 200 µL, i.p.) was 
given 1 h before the challenge with LPS and again 1 h before ROL. Numbers of neutrophils (A), cells 
with distinctive apoptotic morphology (B), and western blot for Mcl-1 (C) were evaluated 4 h later 
drug treatment, i.e., 8 h later LPS challenge. The number of Annexin V+ neutrophils (D) was 
evaluated by flow cytometry 24 h after LPS injection. Representative figures of nonapoptotic 
(asterisk) and apoptotic (arrows) and apoptotic cells inside macrophages (arrowheads) are showed in 
(E) - Original magnifications ×20. Results are expressed as the number of neutrophils/cavity (A), 
percentage of neutrophils with apoptotic morphology (C) and apoptotic neutrophils (Ly6G+/F4/80-
/AnxAV+/7AAD- ( D) and are shown as the mean ± SEM of at least five mice in each group. *P < 
0.05 or ***P < 0.001 when compared with PBS-injected mice; ###P < 0.001 when compared to LPS-
challenged mice. Comparison between the groups ROL and ROL+AnxA1 are highlighted in the 
graphics. For loading control, membranes were reprobed with anti-β-actin. Blots are representative of 
three independent experiments using pooled cells from at least five animals in each experiment. 
 
Figure 7. Effect of treatment with anti-AnxA1 antiserum on db-cAMP-induced resolution of 
acute inflammation. Mice were injected with LPS (250 ng/cavity, i.pl.) or PBS and 4 h later received 
an injection of db-cAMP (6 mg/kg, i.p.). Injections of anti-AnxA1 antiserum (αAnxA1, 200 µL, i.p.) 
was given 1 h before the challenge with LPS and again 1 h before db-cAMP. Numbers of neutrophils 
(A) and cells with distinctive apoptotic morphology (B) were evaluated 4 h later drug treatment, i.e., 8 
h later LPS challenge. Representative figures of nonapoptotic (asterisk) and apoptotic (arrows) and 
apoptotic cells inside macrophages (arrowheads) are showed in (C) - Original magnifications ×20. 
The number of Annexin V+ neutrophils (D) with representative dot plots (E) was evaluated by flow 
cytometry 24 h after LPS injection. Results are expressed as the number of neutrophils/cavity (A), 
percentage of neutrophils with apoptotic morphology (B) and apoptotic neutrophils (Ly6G+/F4/80-
/AnxAV+/7AAD- (D) and are shown as the mean ± SEM of at least five mice in each group. *P < 
0.05, **P <0.01 or ***P < 0.001, when compared with PBS-injected mice; #P < 0.05 when compared 
to LPS-challenged mice. Comparison between the groups db-cAMP and db-cAMP+AnxA1 are 
highlighted in the graphics. 
 
Figure 8. Effect of treatment with rolipram and db-cAMP on neutrophil apoptosis on wild-type 
and AnxA1-knockout mice. WT or AnxA-KO mice were injected with LPS (250 ng/cavity, i.pl.) and 
4 h later received an injection of ROL (6 mg/kg, i.p.) or db-cAMP (4 mg/kg, i.pl.). The cells from 
pleural cavity were harvested and numbers of cells with distinctive apoptotic morphology were 
evaluated 4 h later drug treatment, i.e., 8 h later LPS challenge. Results are expressed as percentage of 
neutrophils with apoptotic morphology and are shown as the mean ± SEM of at least five mice in each 
group. #P < 0.05 or ##P < 0.01 when compared to LPS-challenged mice. 
 
Figure 9. Effect of treatment with rolipram and db-cAMP on human neutrophil apoptosis. 
Neutrophils isolated from human peripheral blood (1 x 106 cell per well) were cultured with LPS (500 





































concentrations (B, C). The cells were also pre-treated with anti-AnxA1 antiserum (100 μg/mL) or 
WRW4 (10 μM), a specific FPR2/ALXR antagonist 1 hour before LPS (D, E, F). Sivelestat (100 
µg/mL) was used as a positive control for neutrophil apoptosis (A). Neutrophils were processed for 
cytospin preparations for apoptosis count. Representative figures of nonapoptotic (asterisk) and  
apoptotic (arrows) neutrophils are show. Original magnifications ×100. **P  0.01 or ***P <0.001 
when compared LPS treated group with untreated (UT) neutrophils. #P < 0.05, ##P < 0.01 and ###P < 
0.001 when compared LPS treated group with drugs-treated neutrophils. The experiments were 
performed in biological quadruplicates.  
 
Figure 10. Proposed mechanism by which rolipram and db-cAMP modulate AnxA1 and 
resolution of acute inflammation. The generation of cAMP is initiated when an extracellular first 
messenger binds to G protein coupled receptor (GPCR) at the plasma membrane, which is coupled to 
a stimulatory G protein α subunit (Gαs). The free Gαs subunit activates the enzyme adenylyl cyclase 
(AC) to convert ATP into cAMP. Forskolin directly activates adenylyl cyclase. Phosphodiesterases 
(PDEs), which degrade cAMP to 5’-AMP, are another regulator of intracellular cAMP levels. PDE 
inhibitors such as rolipram prevent cAMP degradation, resulting in accumulation of intracellular 
cAMP. Cyclic AMP can then to bind and to activate the protein kinase A (PKA), in which in turn 
phosphorylates CREB. P-CREB binds to the cAMP-response element (CRE) on the promoter region 
of AnxA1 gene and promotes transactivation. Dibutyryl cAMP (db-cAMP) is a cell-permeable cAMP 
analog that activates PKA. H89 and cAMPS-Rp are PKA inhibitors. Both rolipram and db-cAMP 
induce AnxA1 expression and its phosphorylation. Phosphorylated AnxA accumulates on the cell 
membrane and is externalized. Once in the extracellular medium, this protein exerts autocrine, 
paracrine and justacrine effects, which are mediated by the FPR2/ALXR. The peptide BOC-1 is a 
nonselective AnxA1 receptor antagonist. Our results shown that AnxA1 is at least one of the 
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